Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer

Annals of Surgical Oncology
Gang ZhaoChun-You Wang

Abstract

DNA hypermethylation is proved to be involved in carcinogenesis. Because chronic pancreatitis (CP) is a consistent risk factor for pancreatic cancer, the possible alteration and tumor contribute effects of hypermethylated in cancer-1 (HIC1) promoter methylation in CP was investigated. Methylation of HIC1 promoter HIC1 and SIRT1 expression were detected in human normal pancreas (NP), CP and pancreatic adenocarcinoma tissues. Furthermore, HIC1/SIRT1 pathway was regulated by demethylating reagent and exogenous expression in PANC-1, BxPC-3 and AsPC-1 cell lines, cell biology behavior including proliferation, apoptosis, cell cycle and senescence were detected. The methylation of HIC1 promoter was demonstrated in 70.3 % pancreatic carcinoma (45 of 64), 47.5 % CP (19 of 40) and 11.4 % NP tissues (4 of 35). Moreover, hypermethylation of HIC1 promoter and deregulation of HIC1 expression in pancreatic cancer were significantly related to high-stage tumor and older patient age. HIC1 promoter hypermethylation was also observed in pancreatic cancer cell lines including PANC-1, BxPC-3 and AsPC-1. Restoration of HIC1 function with 5-aza-dC treatment or pCDNA3FlagHIC1 plasmid transfection leaded to a reduction in cell proliferation, obvious ce...Continue Reading

References

May 20, 1993·The New England Journal of Medicine·A B LowenfelsL Domellöf
Mar 3, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y KanaiS Hirohashi
May 22, 2002·Surgical Oncology·Buckminster Farrow, B Mark Evers
Jul 24, 2002·Gastroenterology Clinics of North America·David C Whitcomb, Katherine Pogue-Geile
Jul 13, 2004·American Journal of Physiology. Gastrointestinal and Liver Physiology·David C Whitcomb
Oct 20, 2004·Cell Cycle·Teeru BihaniAthena W Lin
Feb 3, 2005·Cell Research·Natalia JuraDafna Bar-Sagi
Dec 21, 2006·Archives of Dermatological Research·Yasutoshi HidaSeiji Arase
Jan 11, 2007·Genes & Development·Michael T Hemann, Masashi Narita
Jan 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·Qinghong ZhangRichard H Goodman
Jul 20, 2007·Cancer Research·Derek M HuffmanTim R Nagy
Sep 7, 2007·Biotechnology Journal·Walter StünkelJeanette Wood
Mar 6, 2008·British Journal of Haematology·Christian BritschgiMario P Tschan
Mar 19, 2008·Genes & Development·Kimberly J BriggsD Neil Watkins
Mar 21, 2008·Current Opinion in Cell Biology·Alexandre Prieur, Daniel S Peeper
Aug 30, 2008·The International Journal of Biochemistry & Cell Biology·Capucine FleurielDominique Leprince
Nov 20, 2008·BMB Reports·Eun-Joo Kim, Soo-Jong Um
Jun 6, 2009·Molecular Oncology·Aik Choon TanManuel Hidalgo
Jul 31, 2009·Nature·Toren FinkelRaul Mostoslavsky
Aug 4, 2009·Neoplasia : an International Journal for Oncology Research·Ruo-Chia TsengYi-Ching Wang
Aug 29, 2009·Trends in Endocrinology and Metabolism : TEM·Carles Cantó, Johan Auwerx
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
Jan 29, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hamdy E AbouzeidShaimaa Abdel Rahman

❮ Previous
Next ❯

Citations

Oct 4, 2013·BMC Cancer·Albrecht StenzingerWilko Weichert
Apr 10, 2013·Expert Opinion on Therapeutic Targets·Brian R Rood, Dominique Leprince
May 6, 2015·Epigenomics·Christopher L PinRashid Mehmood
Jul 6, 2016·Oxidative Medicine and Cellular Longevity·Raffaele PalmirottaFranco Silvestris
Dec 3, 2014·The International Journal of Biochemistry & Cell Biology·John A G MoirJelena Mann
Nov 3, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ales CveklAles Cvekl
Jan 19, 2019·Oncology Letters·Shajedul IslamItsuo Chiba
Nov 28, 2019·Epigenomes·Rahul R SinghRick J Jansen
Nov 29, 2016·Clinical Epigenetics·Stine Dam HenriksenOle Thorlacius-Ussing
Sep 1, 2017·International Journal of Cancer. Journal International Du Cancer·Stine Dam HenriksenOle Thorlacius-Ussing

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.